Current read
Clinical traction from 36 study records, 61 active source records, 6 rapid briefs, and 6 timeline events. Evidence maturity is 86/100, human translation signal is 85/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof.
This lane has stronger human/clinical support, but still needs bounded claims.
Commercial bias penalty: 28/100. Confidence: 86/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Muscle, bone, joints, protein, resistance training, obesity-drug lean mass, and mobility-preserving interventions. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 100/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
Resistance training, protein adequacy, joint-repair approaches.
What would move this row up?
Current bottleneck
Replication, durability, and sharper endpoint evidence.
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Intervention trials linking biomarkers to strength, falls, pain, mobility, or independence.
Intervention trials linking biomarkers to strength, falls, pain, mobility, or independence.
Comparative evidence for joint-repair biologics and lean-mass preservation strategies.
Comparative evidence for joint-repair biologics and lean-mass preservation strategies.
Evidence that would change the map
- Raise evidence maturity from 86/100 with better controlled studies or stronger replication.
- Raise human translation from 100/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not confuse body-composition change with full resilience.
- Do not claim preclinical joint repair is available human arthritis reversal.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
Medicare Launched a $50 GLP-1 Access Bridge
CMS launched a temporary GLP-1 Bridge for eligible Part D beneficiaries, but the program is limited, temporary, and not universal Medicare obesity-drug coverage.
Why now
A major cost barrier around obesity pharmacotherapy shifted for a subset of Medicare beneficiaries.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
NIH Prepares First Human Trial for Ultra-Rare Jansen's Disease
NIDCR is preparing a first-in-human trial of PTH-IA for an ultra-rare skeletal disorder with no effective treatment.
Why now
A roughly 30-known-patients-worldwide disease makes this a clean NIH ultra-rare medicine signal.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 30, 2026
Oral FGFR3 Drug Shows Phase 3 Benefit in Children With Achondroplasia
BridgeBio’s once-daily oral infigratinib improved annualized height velocity and body proportionality in a Phase 3 achondroplasia trial published in NEJM.
Why now
Oral therapy could change the treatment-burden conversation for achondroplasia if regulators agree.
- Overclaim risk
- medium-high
- Primary source
- Primary
- Published
- Jun 30, 2026
GLP-1 Drugs Linked to Higher Smell and Taste Disturbance Risk
A large EHR cohort study found GLP-1 RA users with type 2 diabetes had higher documented smell and taste disturbance risk, though absolute rates were low.
Why now
GLP-1 safety signals are socially viral and need careful absolute-risk framing.
- Overclaim risk
- medium-high
- Primary source
- Primary
- Published
- Jun 30, 2026
Generic Tirzepatide Challengers Enter FDA Review
Sandoz and Hybio said FDA accepted generic tirzepatide applications, opening a new phase in the long access fight around Mounjaro and Zepbound.
Why now
GLP-1 attention is shifting from efficacy to access, patents, pricing, supply, and generic strategy.
- Overclaim risk
- medium-high
- Primary source
- Trade news
- Published
- Jun 30, 2026
The Compounded GLP-1 Boom Is Becoming a Patient-Safety and Trust Crisis
The weight-loss drug boom created a shadow market of compounded GLP-1s, fake labels, telehealth claims, dosing confusion, and patients who may not know what they are actually getting.
Why now
Regulatory warnings and investigations are converging on the same problem: patients cannot always tell what product they are receiving.
- Overclaim risk
- medium-high
- Primary source
- Trade news
- Published
- Jun 24, 2026
Latest graph movement
2021 / trial
STEP 1
Semaglutide obesity trial in adults with overweight or obesity without diabetes.
2022 / trial
SURMOUNT-1
Tirzepatide obesity trial broadened the category beyond single-agonist therapy.
2023 / trial
SELECT
Cardiovascular outcomes data in adults with overweight or obesity and established cardiovascular disease without diabetes.
2024 / trial
FLOW
Kidney outcomes data in people with type 2 diabetes and chronic kidney disease.
2024 / regulatory
SURMOUNT-OSA and Zepbound approval
Tirzepatide data and FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity.
2025 / regulatory
ESSENCE and Wegovy MASH approval
Semaglutide evidence and FDA approval for noncirrhotic MASH with moderate-to-advanced fibrosis.
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Alkaline Water Will Not Fix Your pH
Alkaline diets and waters can move urine chemistry and may matter in narrow reflux or kidney-stone contexts. They do not alkalize your blood, cure cancer, detox your body, or override acid-base regulation.
VV Signal Score
54
Early or context-dependent
- Sources
- 12
- Studies
- 10
- Claims
- 10
Vegan Diets Can Be Elite or Deficient
The online vegan war is a perfect nutrition trap: one side pretends plants automatically solve health, the other pretends excluding animal foods guarantees collapse. The evidence supports neither cartoon.
VV Signal Score
70
Promising signal
- Sources
- 14
- Studies
- 13
- Claims
- 10
Calories Are the Accounting System, Not the Whole Metabolic Story
Weight loss requires an energy deficit, but calories alone do not explain appetite, metabolism, food environment, hormones, lean mass, sleep, medications, or long-term maintenance.
VV Signal Score
83
Strong signal
- Sources
- 13
- Studies
- 10
- Claims
- 8
The Carnivore Diet Is a Real Experiment, Not a Settled Science
Carnivore eating may change weight, symptoms, and biomarkers for some people. The direct evidence is still too thin to establish broad benefit or long-term safety.
VV Signal Score
42
Mixed signal
- Sources
- 12
- Studies
- 12
- Claims
- 9
Creatine Beyond Muscle: Cheap Supplement or Overextended Brain Hack?
Creatine is one of the rare supplements where the baseline evidence is not flimsy. That makes the overclaim risk more interesting: strong sports-nutrition evidence is now being stretched into cognition, depression, aging, women’s health, sleep deprivation, and neuroprotection.
VV Signal Score
78
Promising signal
- Sources
- 7
- Studies
- 6
- Claims
- 4
Sauna, Cold Plunge, and Contrast Therapy: Hormesis or Heart-Stress Theater?
Sauna has a stronger long-term cardiovascular and mortality signal than most cold-plunge claims. Cold exposure has acute physiology, mood appeal, and recovery tradeoffs. Contrast therapy adds ritual, but not automatic evidence.
VV Signal Score
57
Early or context-dependent
- Sources
- 7
- Studies
- 7
- Claims
- 4
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
low carb: Insulin and carbohydrate quality matter, but controlled feeding evidence
Insulin and carbohydrate quality matter, but controlled feeding evidence does not support a simple insulin-only explanation of obesity or fat loss.
weight loss: Low-fat and low-carbohydrate patterns can both support weight loss,
Low-fat and low-carbohydrate patterns can both support weight loss, but group-average diet labels are less useful than adherence, food quality, calorie intake, and individual fit.
glp 1: Semaglutide and tirzepatide produce clinically meaningful average weight loss
Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.
glp 1: GLP-1-based therapies have demonstrated outcome benefits beyond weight loss
GLP-1-based therapies have demonstrated outcome benefits beyond weight loss in specific high-risk cardiometabolic populations.
glp 1: Weight maintenance commonly depends on continued treatment, while optimal
Weight maintenance commonly depends on continued treatment, while optimal long-term strategies and lean-mass preservation remain active evidence gaps.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.